These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1138 related articles for article (PubMed ID: 27001573)

  • 1. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
    Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
    J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
    Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
    Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
    Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
    Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-Dimensional Image Fusion of
    Yu Y; Zhang WB; Liu XJ; Guo CB; Yu GY; Peng X
    J Oral Maxillofac Surg; 2017 Jun; 75(6):1301.e1-1301.e15. PubMed ID: 28320612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy.
    Hansen JA; Naghavi-Behzad M; Gerke O; Baun C; Falch K; Duvnjak S; Alavi A; Høilund-Carlsen PF; Hildebrandt MG
    PLoS One; 2021; 16(11):e0260066. PubMed ID: 34793550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.
    Hurley C; McCarville MB; Shulkin BL; Mao S; Wu J; Navid F; Daw NC; Pappo AS; Bishop MW
    Pediatr Blood Cancer; 2016 Aug; 63(8):1381-6. PubMed ID: 27082077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
    Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
    J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis.
    Xiao Y; Wang L; Jiang X; She W; He L; Hu G
    Nucl Med Commun; 2016 Nov; 37(11):1180-8. PubMed ID: 27428888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.
    Zattoni F; Incerti E; Colicchia M; Castellucci P; Panareo S; Picchio M; Fallanca F; Briganti A; Moschini M; Gallina A; Karnes JR; Lowe V; Fanti S; Schiavina R; Rambaldi I; Ficarra V; Evangelista L
    Abdom Radiol (NY); 2018 Sep; 43(9):2391-2399. PubMed ID: 29302738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study.
    Ozkan E; Soydal C; Araz M; Aras G
    Nucl Med Commun; 2012 Sep; 33(9):990-4. PubMed ID: 22842225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
    Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
    Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT.
    Kawanaka Y; Kitajima K; Fukushima K; Mouri M; Doi H; Oshima T; Niwa H; Kaibe N; Sasako M; Tomita T; Miwa H; Hirota S
    Eur J Radiol; 2016 May; 85(5):989-95. PubMed ID: 27130061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Bone Lesions with
    van Es SC; Velleman T; Elias SG; Bensch F; Brouwers AH; Glaudemans AWJM; Kwee TC; Iersel MW; Maduro JH; Oosting SF; de Vries EGE; Schröder CP
    J Nucl Med; 2021 Feb; 62(2):177-183. PubMed ID: 32817140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of ¹⁸F-FDG PET/CT for detection of suspected recurrence in patients with oesophageal carcinoma.
    Sharma P; Jain S; Karunanithi S; Pal S; Julka PK; Thulkar S; Malhotra A; Bal C; Kumar R
    Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1084-92. PubMed ID: 24435775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis.
    Daamen LA; Groot VP; Goense L; Wessels FJ; Borel Rinkes IH; Intven MPW; van Santvoort HC; Molenaar IQ
    Eur J Radiol; 2018 Sep; 106():128-136. PubMed ID: 30150034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.